HB-adMSCs for Parkinson's Disease (PD Trial)

"The goal of this study is to assess vital signs over a 52-week period. Secondary outcomes include changes in the Unified Parkinson's disease Rating Scale (MDS-UPDRS), which includes assessments of motor function, speech, facial expression, rigidity, finger tapping, hand movements, pronation-supination movements of hands, toe tapping, leg agility, arising from chair, gait, freezing of gait, postural stability, posture, global spontaneity of movement (body bradykinesia), postural tremor of the hands kinetic tremor of the hands ,rest tremor amplitude constancy of"

"As of right now, this clinical trial is not looking for new patients. The 6/28/2021 post date was the start of the trial and 7/20/22 was the most recent update. There are 516 other trials currently underway for parkinson disease and 6 more that involve HB-adMSCs if you're interested in exploring additional research opportunities."

"This clinical trial is recruiting 24 participants with [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease) aged 18 to 75. Most importantly, patients are required to meet the following criteria:-Study participant is able and willing to comply with the requirements of this clinical trial.-Study participant must have been diagnosed with early and/or moderate Parkinson's disease at least 6 months before study participation.-Study participants should be able to read, understand and provide written consent.-Male and female participants 18 - 75 years of age.-Female study participants should not be pregnant or plan to become pregnant during study participation and for 6 months after last investigational product"

"Hope Biosciences sponsored the first trial for HB-adMSCs in 2020, which completed its Phase 1 & 2 drug approval stage that same year. Since then, 18297 studies have been completed. Currently, there are 6 live trials for HB-adMSCs across 4 cities and 1 countries."

"Patients that meet the age requirements of 18-75 years old are eligible for this clinical trial. There are 28 other studies available for patients under 18 and 518 studies available for seniors above 65 years old."

"There are six clinical trials currently underway that are studying the effects of HB-adMSCs. None of these studies have progressed to Phase 3 yet. Most of the research is taking place in Sugar Land, Texas; however, there are seven total locations running HB-adMSC clinical trials."

"This Phase 2 trial has not yet demonstrated efficacy, but there is evidence that HB-adMSCs are safe. Therefore, we have rated it a 2."

"Currently, this trial is not recruiting patients. The study was first posted on June 28th 2021 and edited most recently on July 20th 2022. However, there are 516 trials for parkinson disease and 6 HB-adMSC studies that are actively recruiting participants."